Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole.
Itraconazole and fluconazole are triazole compounds recently licensed for the therapy of systemic fungal infections. At 10 micrograms/ml concentrations, itraconazole was found to suppress neutrophil chemotaxis, random movement, deoxyglucose uptake and hexose-monophosphate shunt activity to the same extent as ketoconazole, an older generation azole antifungal. Itraconazole was also found to suppress mitogen-induced lymphocyte transformation to the same extent as ketoconazole at concentrations as low as 1 microgram/ml. By contrast, significant inhibition of both neutrophil and lymphocyte functions was not observed with fluconazole at concentrations as high as 50 micrograms/ml. These results suggest that fluconazole may be less immunotoxic than itraconazole, and may be more suitable for use in immunocompromised patients.
Vuddhakul
V
V
Department of Child Health, University of Queensland, Mater Public Hospital, South Brisbane, Australia.
Mai
G T
GT
McCormack
J G
JG
Seow
W K
WK
Thong
Y H
YH
D000935:Antifungal Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003847:Deoxyglucose / Q000493:pharmacokinetics; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D017964:Itraconazole; D015725:Fluconazole; D003847:Deoxyglucose; D007654:Ketoconazole